Genomic Health has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.
from WSJ.com: US Business http://ift.tt/29yUYsI
via IFTTT
No comments:
Post a Comment